![](/images/graphics-bg.png)
Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1NF-κB Signaling Pathway
المؤلفون المشاركون
Zhang, Jian-ning
Ma, Yang
Wei, Xi-yan
Liu, Ke-yin
Wang, Hao
Han, Hui
Cui, Yi
Zhang, Ming-xiang
Qin, Wei-dong
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-12-31
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Sepsis is a leading cause of death in patients with severe infection worldwide.
Remifentanil is an ultra-short-acting, potent opioid analgesic.
In the study, we aimed to investigate the role and underlying mechanism of remifentanil in lipopolysaccharide- (LPS-) induced inflammation in human aortic endothelial cells (HAECs).
HAECs were pretreated with phosphate-buffered saline (PBS) or remifentanil (2.5 μM) for 30 min, then stimulated by LPS (10 μg/ml) for another 24 h.
Poly(ADP-ribose) polymerase 1 (PARP-1) was inhibited by small interfering RNA (siRNA).
Superoxide anion production and DNA damage were analyzed by dihydroethidium (DHE) staining and comet assay.
The inducible nitric oxide synthase (iNOS), intercellular adhesion molecule 1 (ICAM-1), PARP-1, poly(ADP-ribose) (PAR), and nuclear factor-kappa B p65 (NF-κB p65) expressions were analyzed by RT-PCR or western blotting analysis.
NF-κB p65 nuclear translocation was assessed by immunofluorescence.
Compared with the control group, pretreatment with remifentanil significantly reduced superoxide anion production and DNA damage, with downregulation of iNOS, ICAM-1, and PARP-1 expressions as well as PAR expression.
Moreover, pretreatment with PARP-1 siRNA or remifentanil inhibited LPS-induced NF-κB p65 expression and nuclear translocation.
Remifentanil reduced LPS-induced inflammatory response through PARP-1/NF-κB signaling pathway.
Remifentanil might be an optimal choice of analgesia in septic patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Zhang, Jian-ning& Ma, Yang& Wei, Xi-yan& Liu, Ke-yin& Wang, Hao& Han, Hui…[et al.]. 2019. Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1NF-κB Signaling Pathway. Mediators of Inflammation،Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1192757
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Zhang, Jian-ning…[et al.]. Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1NF-κB Signaling Pathway. Mediators of Inflammation No. 2019 (2019), pp.1-8.
https://search.emarefa.net/detail/BIM-1192757
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Zhang, Jian-ning& Ma, Yang& Wei, Xi-yan& Liu, Ke-yin& Wang, Hao& Han, Hui…[et al.]. Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1NF-κB Signaling Pathway. Mediators of Inflammation. 2019. Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1192757
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1192757
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)